ATE209921T1 - Verwendung von vitamin d und seinen derivaten zur herstellung eines medikamentes zum schutz vor neuronenverlust - Google Patents

Verwendung von vitamin d und seinen derivaten zur herstellung eines medikamentes zum schutz vor neuronenverlust

Info

Publication number
ATE209921T1
ATE209921T1 AT94923484T AT94923484T ATE209921T1 AT E209921 T1 ATE209921 T1 AT E209921T1 AT 94923484 T AT94923484 T AT 94923484T AT 94923484 T AT94923484 T AT 94923484T AT E209921 T1 ATE209921 T1 AT E209921T1
Authority
AT
Austria
Prior art keywords
vitamin
compound
neuron loss
against neuron
protect against
Prior art date
Application number
AT94923484T
Other languages
English (en)
Inventor
Philip W Landfield
Original Assignee
Univ Kentucky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kentucky filed Critical Univ Kentucky
Application granted granted Critical
Publication of ATE209921T1 publication Critical patent/ATE209921T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Signal Processing For Digital Recording And Reproducing (AREA)
  • Moving Of Heads (AREA)
AT94923484T 1993-07-15 1994-07-14 Verwendung von vitamin d und seinen derivaten zur herstellung eines medikamentes zum schutz vor neuronenverlust ATE209921T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9197693A 1993-07-15 1993-07-15
PCT/US1994/007917 WO1995002409A2 (en) 1993-07-15 1994-07-14 Use of vitamin d and derivatives thereof for the manufacture of a medicament for protection against neuron loss

Publications (1)

Publication Number Publication Date
ATE209921T1 true ATE209921T1 (de) 2001-12-15

Family

ID=22230588

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94923484T ATE209921T1 (de) 1993-07-15 1994-07-14 Verwendung von vitamin d und seinen derivaten zur herstellung eines medikamentes zum schutz vor neuronenverlust

Country Status (10)

Country Link
US (1) US5939407A (de)
EP (1) EP0710112B1 (de)
JP (1) JPH09507830A (de)
AT (1) ATE209921T1 (de)
AU (1) AU7333694A (de)
CA (1) CA2167171C (de)
DE (1) DE69429351T2 (de)
ES (1) ES2166377T3 (de)
IL (1) IL110309A0 (de)
WO (1) WO1995002409A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1011683A4 (de) * 1997-05-22 2003-06-11 Cephalon Inc Vitamin d analoge und der wirkung auf neuronen
NZ507449A (en) * 1998-05-15 2003-08-29 Univ Leland Stanford Junior Glucocorticoid receptor antagonists for the treatment of dementia
AU6137801A (en) * 2000-05-09 2001-11-20 Childrens Medical Center Method and composition for the treatment of angiogenesis
US7858602B2 (en) * 2000-10-16 2010-12-28 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
EP1330467B1 (de) * 2000-11-03 2007-05-02 Washington University Östronderivate mit zellschützender wirkung
AU2002228891A1 (en) * 2000-11-17 2002-05-27 Washington University Cytoprotective estrogen derivatives
AU2002303652B2 (en) * 2001-05-04 2006-08-31 Corcept Therapeutics, Inc. Methods for treating delirium using glucocorticoid receptor-specific antagonists
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20050192255A1 (en) * 2003-07-30 2005-09-01 Jin Tian Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
WO2005116047A2 (en) * 2004-05-27 2005-12-08 Migenix Corp. 2-substituted 17-imino estrogen compounds for cytoprotection
AU2006251832A1 (en) * 2005-05-27 2006-11-30 Queen's University At Kingston Treatment of protein folding disorders
JP2007023010A (ja) * 2005-07-19 2007-02-01 Toshiro Azegami 閉経後のホルモンバランス調整及びパーキンソン症の予防改善目的の経口組成物
HUE035852T2 (en) * 2006-04-03 2018-05-28 Accera Inc Use of ketogen compounds to treat memory decline
EP2167098B1 (de) * 2007-06-11 2018-09-05 University Of Southern California Allopregnanolon in einer methode zur verstärkung der neurologischen funktion (alzheimer krankheit)
US20100204192A1 (en) 2007-06-11 2010-08-12 University Of Sourthern California Agents, compositions and methods for enhancing neurological function
US20110306579A1 (en) * 2009-01-30 2011-12-15 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
EP2363119A1 (de) * 2010-03-05 2011-09-07 Centre Hospitalier Universitaire d'Angers Neue pharmazeutische Zusammensetzung, die zur Behandlung von Patienten mit neurodegenerativen oder neurovaskulären Erkrankungen geeignet ist
FR2965178B1 (fr) * 2010-09-29 2012-10-05 Sebastien Lasnier Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer
ES2951664T3 (es) * 2011-09-08 2023-10-24 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
EP3932932A1 (de) 2013-03-13 2022-01-05 Sage Therapeutics, Inc. Neuroaktive steroide und verfahren zur verwendung davon
US20140296190A1 (en) * 2013-03-27 2014-10-02 Dsm Ip Assets B.V. Marketing the use of 25-hydroxyvitamin d3 to enhance cognition
CN105208878A (zh) * 2013-03-27 2015-12-30 帝斯曼知识产权资产管理有限公司 25-羟基维生素d3用于增强执行功能的用途
ES2536256B2 (es) 2013-11-20 2016-02-01 Universidade De Santiago De Compostela Análogos de vitamina d con interés farmacéutico
EP4306114A1 (de) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxysterole und verfahren zu ihrer verwendung
MA42409A (fr) 2015-07-06 2018-05-16 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
RU2021100620A (ru) 2015-07-06 2021-01-29 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
MY197698A (en) 2015-07-06 2023-07-06 Sage Therapeutics Inc Oxysterols and methods of use thereof
LT3436022T (lt) 2016-04-01 2022-06-27 Sage Therapeutics, Inc. Oksisteroliai ir jų panaudojimo būdai
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2884071T3 (es) 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
CN110023323A (zh) 2016-09-30 2019-07-16 萨奇治疗股份有限公司 C7取代的氧固醇及其作为nmda调节剂的方法
MA46565A (fr) 2016-10-18 2019-08-28 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
CA3041088C (en) 2016-10-18 2024-05-21 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US20230218581A1 (en) 2020-04-24 2023-07-13 The Johns Hopkins University Compositions and methods comprising dendrimers and therapeutic agents
WO2023028554A1 (en) 2021-08-25 2023-03-02 Neuraly, Inc. Glp-1r agonists for use in a treatment of neurological impairment associated with viral infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63104926A (ja) * 1986-10-21 1988-05-10 Teijin Ltd 老年性痴呆症治療又は予防剤
FR2639225B1 (fr) * 1988-11-21 1993-05-21 Centre Nat Rech Scient Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
US4957909A (en) * 1989-05-04 1990-09-18 American Home Products Corporation Benzobicycloalkane derivatives as anticonvulsant neuroprotective agents
US5089517A (en) * 1990-08-03 1992-02-18 The Board Of Trustees Of The Leland Stanford Junior University Neuroprotection by indolactam v and derivatives thereof
US5168103A (en) * 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
US5196421A (en) * 1991-06-05 1993-03-23 Eli Lilly And Company Excitatory amino acid receptor antagonists in methods for the use thereof
US5153196A (en) * 1991-06-05 1992-10-06 Eli Lilly And Company Excitatory amino acid receptor antagonists and methods for the use thereof

Also Published As

Publication number Publication date
ES2166377T3 (es) 2002-04-16
AU7333694A (en) 1995-02-13
US5939407A (en) 1999-08-17
CA2167171A1 (en) 1995-01-26
WO1995002409A2 (en) 1995-01-26
DE69429351T2 (de) 2002-05-23
EP0710112B1 (de) 2001-12-05
CA2167171C (en) 2007-04-24
WO1995002409A3 (en) 1995-04-27
IL110309A0 (en) 1994-10-21
JPH09507830A (ja) 1997-08-12
DE69429351D1 (de) 2002-01-17
EP0710112A1 (de) 1996-05-08

Similar Documents

Publication Publication Date Title
ATE209921T1 (de) Verwendung von vitamin d und seinen derivaten zur herstellung eines medikamentes zum schutz vor neuronenverlust
BR0309623A (pt) Agentes que regulam. inibem ou modulam a atividade e/ou a expressão do fator de crescimento de tecido conjuntivo (ctgf) como um único meio de diminuir a pressão intraocular e tratar retinopatias glaucomatosas/neuropatias ópticas
MD895B2 (ro) Preparat sinergetic şi procedeu de distrugere selectivă a buruienilor
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
MX9606404A (es) Composiciones farmaceuticas y metodos para formular trasnduccion de señales.
DE3687501D1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eines arneimittels zur behandlung von komplikationen bei diabetes mellitus.
CA2202879A1 (en) Calcium receptor-active compounds
ATE239462T1 (de) Verwendung von kreatinanalogen zur behandlung von störungen des glukosemetabolismus
ATE467616T1 (de) Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
DE69310634D1 (de) Verwendung von Taxol zur Herstellung eines Arzneimittels zur Behandlung von Krebs
ATE206919T1 (de) Verwendung des wirkstoffs flupirtin zur herstellung eines arzneimittels zur bekämpfung von muskelverspannungen
ATE286384T1 (de) Formulierung mit verzögerter freisetzung enthaltend kollagen und glykosaminoglykan
NO20005161L (no) N,N-disubstituerte amider som inhiberer bindingen av integriner til deres reseptorer
DE69324859D1 (de) Verwendung von Lipid-gebundener Glykoaminoglykanen zur Behandlung der rheumatoider Arthritis
AU1876788A (en) Methylene phosphonoalkylphosphinates, pharmaceutical compositions , and methods for treating abnormal calcium and phosphate metabolism
DE68914922D1 (de) Verwendung von Inositoltrisphosphat zur Herstellung eines Arzneimittels gegen Knochenerkrakungen.
ATE98488T1 (de) Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit beta-blockern oder bradycardica.
DE69330150D1 (de) Pharmazeutische Zusammensetzungen zur transdermalen Verabreichung von Melatonin und/oder seine Analoge
DE59206924D1 (de) Ein flurbiprofen enthaltendes akutarzneimittel und seine verwendung
AU6408894A (en) 2-substituted morpholine and thiomorpholine derivatives as gaba-b antagonists
DE69518159T2 (de) Mittel zur vorsorge und heilung von typ i allergischen krankheiten
BR9811829A (pt) Processos para fumegação do solo contendo organismos deletérios controlando ao mesmo tempo a fitotoxicidade, e, para controlar organismos deletérios no solo
DE69307197D1 (de) Verwendung von 24,25-Dihydroxyvitamin-D3 zur Herstellung eines Arzneimittel zur Behandlung der Rachitis
DE69628430D1 (de) Verwendung von lactoferrin zur prävention des nachoperativen astigmatismus
DE69121940D1 (de) Derivate des Hydantoins zur Verwendung als hypoglycemische und/oder hypolipidemische Wirkstoffe

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties